Valuation: Agenus Inc.

Market Cap 305M 276M 255M 230M 434M 28.71B 449M 3.07B 1.22B 15.34B 1.14B 1.12B 48.68B P/E 2026 *
21.4x
P/E 2027 * -13.2x
Enterprise Value 305M 276M 255M 230M 434M 28.71B 449M 3.07B 1.22B 15.34B 1.14B 1.12B 48.68B EV / Sales 2026 *
2.33x
EV / Sales 2027 * 2.47x
Free-Float
93.76%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Agenus Inc.

1 day-2.04%
1 week-5.87%
Current month-1.61%
1 month+3.54%
3 months-8.06%
6 months+87.99%
Current year+114.33%
1 week 6.5
Extreme 6.5
7.65
1 month 6
Extreme 6
7.65
Current year 2.71
Extreme 2.71
10.31
1 year 2.71
Extreme 2.71
10.31
3 years 1.38
Extreme 1.38
19.69
5 years 1.38
Extreme 1.38
74.5
10 years 1.38
Extreme 1.38
135.8
Manager TitleAgeSince
Chief Executive Officer 73 30/03/1994
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 31/10/2021
Director TitleAgeSince
Chairman 73 03/11/2010
Director/Board Member 68 07/03/2007
Director/Board Member 68 06/12/2006
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Free

Director

1,179 0.0026%
01/10/26 Free

Director

4,443 0.0098%
10/08/26 Free

Chief Executive Officer

1,971,500 4.4054%
Change 5-day change 1-year change 3-year change Capi.($)
-2.04%-5.87%+55.07%-53.96% 305M
-2.69%-0.48%+53.97%+70.99% 66.33B
-0.92%+7.67%+12.64%+92.55% 60.62B
0.00%+0.39%+22.34%+90.83% 55.5B
+0.14%+2.35%+13.86%+106.64% 47.58B
-2.21%-2.47%+20.18%+32.24% 43.69B
-2.30%-10.40%+154.30%+725.54% 37.27B
+2.15%+1.42%+14.58%+54.23% 36.57B
-2.32%-2.24%+76.50%+54.55% 32.22B
+2.62%+5.90%-37.29%+393.72% 26.58B
Average -0.76%-0.54%+38.62%+156.73% 41B
Weighted average by Cap. -0.83%+0.20%+36.64%+155.09%

Financials

2026 *2027 *
Net sales 131M 118M 110M 98.8M 186M 12.32B 193M 1.32B 522M 6.58B 490M 480M 20.89B 123M 112M 103M 93.2M 176M 11.62B 182M 1.24B 492M 6.21B 462M 453M 19.7B
Net income 25.5M 23.11M 21.37M 19.28M 36.34M 2.4B 37.62M 257M 102M 1.28B 95.69M 93.66M 4.08B -30.3M -27.46M -25.4M -22.91M -43.18M -2.86B -44.7M -305M -121M -1.53B -114M -111M -4.84B
Net Debt - -
Projected Income Statement - Annual - Agenus Inc.
Logo Agenus Inc.
Agenus Inc. is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. The Company's primary business is immuno-oncology, which is advancing antibody-based programs to activate innate and adaptive immunity, overcome tumor immune evasion and expand the population of patients from immunotherapy. Its lead clinical program is botensilimab, alone and in combination with balstilimab, is a clinical-stage immuno-oncology asset which may be used as standalone agents or be complimentary to botensilimab plus balstilimab. Its internal discovery and translation platforms support target identification, antibody generation, biomarker analysis, and candidate selection. The Company's clinical and preclinical portfolio include agents directed to CTLA-4, PD-1, CD137, CD73/TGF-beta, ILT2, LAG-3, TIM-3, and TIGIT, all of which remain as proprietary assets of Agenus.
Employees
81
Date Price Change Volume
13/11/26 US$6.730 -2.04% 465,153
12/11/26 US$6.870 -4.85% 499,051
11/11/26 US$7.220 +2.85% 430,505
10/11/26 US$7.020 -1.82% 691,627
09/11/26 US$7.150 0.00% 840,872
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
MarketScreener Ratings - Agenus Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
6.730USD
Average target price
27.00USD
Spread / Average Target
+301.19%
  1. Stock Market
  2. Stocks
  3. AGEN Stock